Loading...
•
Jun 30
Korro Bio Q2 2025 Earnings Report
Posted a wider net loss for Q2 2025 due to increased R&D and G&A spending despite modest collaboration revenue gains.
Key Takeaways
Korro Bio reported a Q2 2025 net loss of $25.8M on $1.46M in collaboration revenue, driven by higher R&D and G&A expenses. Cash and marketable securities ended at $119.6M, expected to support operations into 2027.
Net loss for Q2 2025 widened to $25.8M from $21.8M a year ago.
Collaboration revenue was $1.46M, up from $0 last year.
R&D expenses rose to $21.0M, driven by increased personnel and preclinical development activity.
Cash and marketable securities stood at $119.6M, expected to fund operations into 2027.
Korro Bio
Korro Bio
Forward Guidance
Korro expects interim KRRO-110 data in H2 2025, plans to announce a rare metabolic disorder candidate by year-end, and maintains strong funding runway through 2027.
Positive Outlook
- KRRO-110 Phase 1/2a interim data readout expected in H2 2025
- EMA granted Orphan Drug Designation for KRRO-110
- Collaboration with Novo Nordisk progressing across two programs
- Rare metabolic disorder candidate announcement expected by year-end
- Strong cash position expected to fund operations into 2027
Challenges Ahead
- Increased R&D and G&A costs contributing to widened net loss
- No commercial product revenue yet; dependent on collaborations
- Clinical and regulatory risks may impact program timelines
- Currency and market fluctuations led to slight comprehensive loss expansion
- Dependence on future milestone achievements for program progression